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  39 
ABSTRACT 40 
 41 
The new compound [Pt2(4-FC6H4)4(μ-SEt2)2] (A) was prepared and fully characterized. The reactions 42 
of compound A with ligands ArCH=NCH2CH2NMe2 (Ar = 2-BrC6H4, 1a; 2,6-Cl2C6H3, 1b; 4-43 
ClC6H4, 1c; 2-Cl,6-FC6H3, 1d) were studied under different conditions and produced platinum(II) 44 
compounds [Pt(4-FC6H4)2(ArCH=NCH2CH2NMe2)] (2b−2d), containing a bidentate [N,N′] ligand, as 45 
well as cyclometalated platinum(IV) or platinum(II) compounds such as [PtBr(4-46 
FC6H4)2(C6H4CH=NCH2CH2NMe2)] (4a) or [PtCl{(3-FC6H3)(2-XC6H3)CH=NCH2CH2NMe2}] 47 
(5b: X = Cl; 5d: X = F), containing a tridentate [C,N,N′] ligand and either a five (4a) or a seven (5b, 5d) 48 
membered metallacycle. These compounds exhibit a great antiproliferative activity against non-small 49 
lung cancer cells (A549), and the best result was obtained for compound 2c (IC50 = 0.3 ± 0.1 μM). 50 
While compounds 5 alter the mobility of plasmid DNA in a similar way to cisplatin, compound 4 was 51 
less efficient in removing the supercoils from DNA. In spite of the very low IC50 value obtained for 52 
compound 2c, this compound does not interact with DNA, and it is neither an intercalator nor a 53 
topoisomerase I inhibitor. 54 
 55 
 56 
  57 
INTRODUCTION 58 
 59 
Nowadays platinum(II) complexes (cis-, carbo-, and oxaliplatin) dominate the field of metal-based 60 
chemotherapy in worldwide cancer treatment protocols.1 However, major limitations of these drugs are 61 
(i) dose-limiting severe toxicities, (ii) poor bioavailability, and (iii) intrinsic or acquired resistance.2,3 62 
As a consequence, different approaches have emerged to improve the cytotoxic profile of these 63 
anticancer platinum compounds.4 Relevant strategies are focused on (i) the stabilization of the Pt(II) ion 64 
in the complexes, (ii) the design of Pt(IV) complexes as prodrugs, and (iii) the exploitation of the 65 
promising properties associated with organometallic compounds based not only on platinum but also on 66 
other metal ions such as palladium, ruthenium, gold, copper, or iron. Cyclometalated platinum(II) 67 
complexes containing either bidentate [C,N]5 or terdentate [C,N,N′]6 ligands have been recently 68 
screened against tumor cells with very promising outcomes. In these compounds, the presence of a 69 
σ(Pt−C) bond increases the stability of the complexes, thus allowing them to reach the cell unaltered. 70 
Furthermore, the aromatic groups in the cyclometalated ligand might favour intercalative binding to 71 
DNA through π−π stacking,7 while the labile positions in the coordination sphere of the platinum atom 72 
favor covalent coordination to DNA as for cisplatin. Therefore a high cytotoxic activity may result from 73 
the combined effect of intercalation and platination operating for cyclometalated platinum 74 
compounds.5,6a On the other hand, platinum(IV) complexes, able to produce Pt(II) species by reductive 75 
elimination8 or photoactivation,9 offer several potential advantages. They are stable enough to be 76 
administered orally, their stability should result in diminished side effects, and they are amenable to 77 
structural modifications via the axial ligands, which can be used to improve their pharmacological 78 
properties. 79 
In recent years we have been involved in the use of diarylplatinum(II) complexes as precursors in the 80 
synthesis of [C,N,N′] cyclometalated platinum(II) and platinum(IV) compounds10,11 and the study of 81 
the mechanisms involved in these processes.12,13 In particular, along these studies, a novel class of 82 
seven-membered platinacycles has been obtained in a reaction involving formation of a Caryl−Caryl 83 
bond, and these compounds were shown to display a remarkable antiproliferative activity, even greater 84 
than cisplatin, in several human cancer cell lines.6a In order to further explore this area, we undertook a 85 
project aimed at the preparation of a new precursor, [Pt2(4-FC6H4)4(μ-SEt2)2] (A), analogous to 86 
compound [Pt2(4-MeC6H4)4(μ-SEt2)2] previously used as metalating agent.11 Binuclear compound A, 87 
upon reaction with adequate dinitrogen ligands, should produce new series of organometallic platinum 88 
complexes potentially useful as antitumor agents. In addition, the presence of a fluoro substituent in the 89 
aryl ligands of compound A should allow an analysis on the importance of the electronic effects in the 90 
subsequent reactions. Interestingly, several examples of biologically active platinum fluoroaryl 91 
compounds have been previously reported.5l‑o,14 Moreover, the presence of the NMRactive 19F 92 
nucleus will provide an additional spectroscopic handle to characterize the obtained compounds.15,16 93 
An additional interest in this system relies on the fact that fluoro substituents may enhance the binding 94 
efficacy and selectivity in pharmaceuticals.17 95 
The results presented here include the synthesis of the new dimer A, which was found to be an adequate 96 
precursor for the synthesis of several organoplatinum compounds such as diarylplatinum(II) compounds 97 
containing a bidentate [N,N′] ligand (2b−2d) and cyclometalated platinum(II) (5b, 5d) and platinum(IV) 98 
(4a) compounds containing a terdentate [C,N,N′] ligand. Their antiproliferative activity against the A549 99 
human lung cancer cell line has been investigated by means of the MTT colorimetric assay. 100 
Additionally, electrophoretic DNA migration studies, in the absence and in the presence of 101 
topoisomerase I, have been performed, in order to get further insights into the biological behavior of the 102 
synthesized compounds. 103 
.  104 
RESULTS AND DISCUSSION 105 
 106 
Synthesis and Characterization of Platinum Compounds. Although the synthesis of compound cis-107 
[Pt(4-FC6H4)2(SMe2)2] has been recently reported,18 our target compound A has not been described 108 
so far. The dinuclear compound [Pt2(4-FC6H4)4(μ-SEt2)2] (A) was obtained from the reaction of cis-109 
[PtCl2(SEt2)2] with 4-fluorophenyllithium, prepared in situ, and was fully characterized including 110 
singlecrystal X-ray diffraction analysis (Figure 1). Suitable crystals of compound A were grown from 111 
dichloromethane−methanol at room temperature as the solvate A·CH2Cl2. The crystal structure is 112 
composed of discrete molecules held together by van der Waals interactions. Both platinum atoms 113 
display square-planar coordination geometry, while the sulfur atoms are tetrahedrically bonded to both 114 
platinum centers and two ethyl groups. Bond parameters are similar to those found for the analogous 115 
compound [Pt2(4-MeC6H4)4(μ-SEt2)2], whose structure has been previously reported.19 In particular, 116 
the Pt(1)···Pt(2) separation is 3.605 Å. The mean planes of the para-fluorophenyl groups form dihedral 117 
angles of 85.9(3)°, 78.6(3)°, 66.3(3)°. and 84.9(3)° with the Pt2S2 plane. 118 
Ligands ArCH=NCH2CH2NMe2 (Ar = 2-BrC6H4, 1a; 2,6-Cl2C6H3, 1b; 4-ClC6H4, 1c; 2-Cl,6-119 
FC6H3, 1d) were selected for this study since the presence of two nitrogen atoms allows formation of a 120 
[N,N′]-chelate upon coordination to platinum and further reaction should produce cyclometalated 121 
platinum- (II) or platinum(IV) compounds in agreement with previous studies for similar systems.20 122 
The presence of different substituents in the ortho positions of the aryl ring (Br, Cl, or H) is determinant 123 
in the reaction pathway and the nature of the final products of such reactions. 124 
The reactions of compound A with ligands 1a−1d are summarized in Scheme 1. The reaction of [Pt2(4-125 
FC6H4)4(μ- SEt2)2] (A) with imines 1b−1d carried out in toluene at room temperature produced 126 
compounds of general formula [Pt(4-FC6H4)2(ArCH=NCH2CH2NMe2)] (2b−2d). For 1a, the C−Br 127 
bond in the ortho position is easily activated at room temperature to produce cyclometalated 128 
platinum(IV) compound [PtBr(4-FC6H4)2(C6H4CH=NCH2CH2NMe2)] (4a). For this reason, 129 
compound 2a was not isolated, although the reaction is expected to proceed through this species in 130 
agreement with previous mechanistic studies for related systems.13 Compounds 2b−2d were 131 
characterized by usual techniques, and in addition, 2d was also characterized crystallographically. The 132 
1H NMR spectra of compounds 2b and 2c display only one group of signals, which was assigned, in 133 
agreement with the observed 3J(H−Pt) values for the imine hydrogen (ca. 50 Hz), to the E isomer. In 134 
contrast, compound 2d was obtained as a mixture of Z and E isomers, as readily deduced from the 1H 135 
and 19F NMR spectra. This result prompted us to monitor by 1H NMR spectroscopy the stability of 136 
compounds 2b and 2c in CDCl3 solution. While compound 2c was stable in solution as the E isomer, 137 
compound 2b gave after several hours at room temperature a mixture of three compounds, as evidenced 138 
by the three resonances observed in the imine region. These were assigned, based on the chemical shifts 139 
and the 3J(H−Pt) values, to isomer E of compound 2b initially present, to the Z isomer (δ = 8.17 ppm, 140 
3J(H−Pt) = 28 Hz), and to the platinum(IV) species 4b (δ = 9.29 ppm, 3J(H−Pt) = 48 Hz) arising from 141 
intramolecular C−Cl bond activation. After several days at room temperature, 4b was the major 142 
component, the ratio E:Z was 1:2.2, and a new peak corresponding to 5b was also observed. Formation 143 
of the Z isomer releases the steric congestion by placing the aryl group away from the platinum atom; 144 
however, formation of compound 4b takes place from the E isomer. These results support the reaction 145 
sequence shown in Scheme 2, in agreement with previously reported mechanisms for analogous 146 
systems.12,13 147 
Suitable crystals of compound 2d were grown in dichloromethane−methanol at room temperature. The 148 
crystal structure is composed of discrete molecules held together by van der Waals forces. The 149 
molecular structure (Figure 2) consists of the E isomer, and bond distances and angles are similar to 150 
those reported for analogous compounds. In particular, the angles CPtC and CPtN are close to 90°, while 151 
the bite angle NPtN is 80.62°. The chelate ring is nearly coplanar with the coordination plane (dihedral 152 
angle 10.5(2)°), and the parafluorophenyl groups trans to the imine and to the amine are tilted 89.6(3)° 153 
and 64.4(3)°, respectively, to that plane. This arrangement allows for an intramolecular π−π stacking21 154 
between the C7−C12 and the C16−C21 rings, the distance being 3.663(4) Å. 155 
As stated above, the reaction of precursor A with ligand 1a produced a cyclometalated platinum(IV) 156 
compound containing a terdentate [C,N,N′] cyclometalated ligand. Compound 4a was fully 157 
characterized including X-ray molecular structure determination of the crystals grown in 158 
dichloromethane−methanol. Multinuclear (1H, 19F, 13C, and 195Pt) NMR spectra indicated formation 159 
of a single isomer, and bidimensional 1H−1H COSY and NOESY experiments allowed the assignment 160 
of all signals observed in the 1H NMR spectrum. The presence of eight cross-peaks in the aromatic 161 
region of the 1H−13C HSQC is also consistent with the proposed structure. All observed coupling 162 
constants are in the range expected for monofluorinated aromatic compounds22 and in good agreement 163 
with the values reported for cyclometalated compounds.23 In addition, the chemical shift of the 164 
observed signal in the 195Pt NMR spectra (δ = −1929.6 ppm) is consistent with the presence of a 165 
platinum(IV) compound.24 166 
The crystal structure is composed of discrete molecules held together by van der Waals interactions. The 167 
molecular structure (Figure 3) confirmed the proposed structure in which the platinum atom displays an 168 
octahedral coordination with the three Pt−C bonds in a fac arrangement. The Pt−C and Pt−N distances 169 
are in the expected range, and the coordination angles involving the mer-[C,N,N′] are smaller than 90° 170 
(C(1)−Pt−N(1) = 81.1(2)° and N(1)−Pt−N(2) = 78.6(2)°). 171 
As indicated above, the reactions of ligands 1b−1d with precursor A in toluene at room temperature 172 
gave compounds 2b−2d, in which the ligands act as bidentate [N,N′] ligands; further reaction of these 173 
compounds was tested in refluxing toluene. As reported for analogous systems,10,11 compound 2c is 174 
expected to produce under these conditions a five-membered cyclometalated platinum(II) compound, 3c. 175 
In the present case, this compound could only be characterized in solution by 1H and 19F NMR spectra, 176 
but could not be isolated in a pure form. Residual amounts of the coordination compound 2c were 177 
present after a reaction time of six hours under reflux. Attempts to achieve full conversion of 2c into 3c 178 
using longer reaction times as well as attempts to purify compound 3c were unsuccessful and result in 179 
decomposition with formation of metallic platinum. Formation of compounds analogous to 3c has been 180 
reported, along with reductive elimination of either benzene or toluene, from complexes such as cis-181 
[PtPh2(SMe2)2]10,25 or [Pt2(4-MeC6H4)4(μ-SEt2)2].11 In addition several compounds of general 182 
formula [PtAr2L2] (L = dmso or SMe2) have been used as metalating agents in the synthesis of 183 
cycloplatinated compounds.26 The failure to obtain pure 3c could be related to the low nucleophilic 184 
character of A that renders the intramolecular C−H bond activation more difficult than for the previously 185 
reported precursors. In this sense, it has been previously reported that only intramolecular C−Br bond 186 
activation, and not C−Cl or C−H bond activation, took place when cis-[Pt(C6F5)2(SMe2)2] was used as 187 
starting material in analogous reactions.27 188 
When toluene solutions of 2b or 2d were heated at reflux temperature for six hours, compounds 5b and 189 
5d, depicted in Scheme 1, were obtained as pure solids. These [C,N,N′] cyclometalated platinum(II) 190 
compounds containing a sevenmembered metallacycle are formed from the corresponding compounds 2 191 
in a process involving intramolecular C−Cl bond activation to produce a platinum(IV) cyclometalated 192 
compound, which further reacts to produce compound 5 and eliminates fluorobenzene, as depicted in 193 
Scheme 2 for 2b. Alternatively, compounds 5 could also be obtained in a one-pot procedure after stirring 194 
for four hours a toluene mixture of compound A and the corresponding ligand. Compounds 5b and 5d 195 
were characterized by NMR spectra (1H, 19F, and 195Pt). The δ(195Pt) values are in the range expected 196 
for platinum(II) compounds,24 and in the 1H NMR spectra the nonequivalence of the protons in both 197 
the methyl and the methylene groups indicates that the molecule deviates from planarity. In addition, 198 
two-dimensional 1H−1H COSY and NOESY were also carried out for 5d in order to achieve a complete 199 
assignment. Moreover, a 1H−13C HSQC heterocorrelation evidenced the presence of six cross-peak 200 
signals in the aromatic region for 5d. 201 
Crystals of 5d were grown in dichloromethane−methanol at room temperature. In spite of the disorder 202 
problems encountered, the obtained molecular structure (Figure 4) confirms the geometry predicted by 203 
NMR spectroscopy. The platinum atom displays an approximately square-planar coordination with a 204 
terdentate [C,N,N′] and a chloro ligand. As expected, the seven-membered platinacycle includes a biaryl 205 
fragment, and the position of the fluoro substituent (F1) in para position to the newly formed 206 
Caryl−Caryl bond and meta to the platinum atom supports the mechanism previously suggested for 207 
analogous reactions.13 The process shown in Scheme 3 takes place through reductive coupling of one 208 
parafluorobenzene ligand and the aryl ring of the imine ligand to produce a biaryl moiety, which is 209 
consequently cyclometalated with elimination of fluorobenzene. 210 
Biological Studies. In this work, a set of compounds with different properties (2b, 2c, 2d, 4a, 5b, and 211 
5d) and the corresponding free ligands (1a−1d) were evaluated in vitro to assess their activity on the 212 
inhibition of A549 human lung cancer cell proliferation, using cisplatin as positive control. Compounds 213 
2b−2d are organometallic platinum(II) compounds with one labile position (the dimethylamino 214 
fragment), compounds 5b and 5d are cyclometalated platinum(II) compounds containing two labile 215 
positions (both the chloro ligand and the dimethylamino fragment), and compound 4a is a 216 
cyclometalated platinum(IV) compound with a fac-PtC3 arrangement and a meridional [C,N,N′] 217 
terdentate ligand, thus leaving one bromide and one aryl ring as axial ligands. Their effect on the growth 218 
of the selected cell line was evaluated after 72 h, and the results are displayed in Figure 5. The obtained 219 
IC50 values resulting from an average of two experiments are shown in Table 1. 220 
It can be seen from Table 1 that compounds 5b and 5d exhibit a great antiproliferative activity and lower 221 
IC50 values than cisplatin itself. These compounds show little difference in their cytotoxic effectiveness 222 
among them and when compared with similar seven-membered platinacycles previously described. 6a 223 
Although the presence of fluorine substituents could favour DNA binding, no increase in potency is 224 
observed for compounds 5b and 5d, containing fluoro substituents. As previously reported,6a the seven-225 
membered metallacycles are not planar, the tilt angle between both aryl rings contained in the seven-226 
membered ring is in the range 50.6−54.2°, and consequently, intercalative binding to DNA is not 227 
expected. Compounds 2b and 2d show a notable antiproliferative activity with lower IC50 values than 228 
that of cisplatin. With regard to the same standard reference, compound 2c exhibited a ca. 50-fold 229 
increase in potency. Interestingly compounds 2b−2d have a very similar structure and only differ in the 230 
substitution pattern in the imine aryl group. However, the presence of two substituents in the ortho 231 
positions for 2b and 2d could favor E−Z isomerization around the imine bond or even formation of a 232 
platinum(IV) compound as depicted in Scheme 2 for 2b. Complex 2c (without an ortho substituent) 233 
turned out to be ca. 20-fold more active than 2b and ca. 40-fold more active than 2d. 234 
Most evidence to date indicates that platinum(IV) complexes exhibiting symmetrical axial ligands (Cl, 235 
OH, and OAc) are reduced under physiological conditions by biologically relevant reducing agents 236 
(ascorbic acid, glutathione, metallothionein) to release two axial ligands and yield the cytotoxic 237 
platinum(II) species.8a Investigations with a series of three model Pt(IV) complexes with axial chloro, 238 
acetato, and hydroxo ligands revealed that they have reduction potentials such that the ease of reduction 239 
follows the trend Cl > OAc > OH.8j In addition, the difficulty of reduction of Pt(IV) analogues 240 
exhibiting OH−ligands has been correlated with good in vivo biological activity.8k However it was 241 
found recently that redox potential does not always correlates with the rate of reduction of the 242 
platinum(IV) complexes, and also the precise mechanisms of reduction are not always fully 243 
understood.8e,f  244 
On the other hand, there are no structure−activity rules for platinum(IV) complexes per se, except that 245 
the platinum(II) congeners used for constructing a platinum(IV) complex must be active.8a 246 
Furthermore, to the best of our knowledge, no cytotoxicity has been evaluated so far for [C,N,N′]-247 
cyclometalated Pt(IV) complex. Therefore we intended to determine within this project if it is possible 248 
that unsymmetrical monomeric Pt(IV) complexes, featuring halide and 4-fluorophenyl as axial ligands, 249 
exhibit cytotoxicity versus the cell line selected (A549 human lung cancer). Interestingly the Pt(IV) 250 
complex 4a synthesized in this study exhibited IC50 values in non-small lung cancer cells (A549) very 251 
close to that of the standard reference cisplatin. 252 
The effect of binding of the compounds investigated in this study on supercoiled DNA was determined 253 
by their ability to alter the electrophoretic mobility of pBluescript plasmid DNA: supercoiled closed 254 
circular (ccc) and open circular (oc) forms. Figure 6 shows the electrophoretic mobility of native 255 
pBluescript DNA incubated with the synthesized compounds (2b, 2c, 2d, 4a, 5b, and 5d) at increasing 256 
amounts ranging from 0 to 200 μM. To provide a basis for comparison, incubation of DNA with 257 
cisplatin and ethidium bromide (EtB) was also performed. As expected, cisplatin greatly altered the 258 
electrophoretic mobility of pBluescript DNA at all concentrations tested. At concentrations up to 50 μM 259 
none of the assayed compounds produced a significant effect on the electrophoretic mobility of native 260 
pBluescript DNA. Compounds 5b and 5d greatly alter the mobility of plasmid DNA at 50 μM, and at 261 
100 μM concentration, the rate of migration of the supercoiled band (ccc) decreases even more and 262 
tends to approach that of the nicked relaxed band (oc). Platinum(IV) compound 4a displayed a much 263 
lower effect on plasmid DNA mobility, while compounds 2b−2d did not modify the DNA migration in 264 
spite of their low IC50 values. These results indicated that compounds 5 alter the electrophoretic 265 
mobility of pBluescript plasmid DNA and hence interact with DNA like the standard reference, 266 
cisplatin. However, compounds 2 and 4 showed a weak effect on DNA electrophoresis, pointing out 267 
another mechanism of action or another biomolecular target.  268 
Since compound 2c was found to be very active (IC50 = 0.3 μM) against A549 lung cancer cells, and 269 
π−π stacking interactions are plausible for these types of compounds, as observed in the crystal structure 270 
of compound 2d, we hypothesized that compounds 2 might behave as intercalating agents. Although 271 
intercalation has been traditionally associated with molecules containing fused bi- or tricyclic ring 272 
structures, atypical intercalators might be more prevalent than originally thought.28 In order to ascertain 273 
whether compound 2c could be a DNA intercalator, a topoisomerase-based gel assay was performed 274 
upon this compound.29,30 Figure 7 shows the electrophoretic mobility of supercoiled DNA treated with 275 
topoisomerase I in the presence of compound 2c at increasing amounts ranging from 10 to 100 μM. To 276 
provide a basis for comparison, unwinding assays with etoposide (100 μM) and ethidium bromide (10 277 
μM) as examples of nonintercalative and intercalative drugs, respectively, were also performed. Results 278 
presented in Figure 7 showed that 2c does not prevent unwinding of DNA by the action of 279 
topoisomerase I, indicating that this compound is not an intercalator nor an inhibitor of topoisomerase I. 280 
 281 
 282 
  283 
CONCLUSIONS 284 
 285 
The new compound [Pt2(4-FC6H4)4(μ-SEt2)2] (A) appears to be a suitable precursor for the synthesis 286 
of several types of organometallic species such as diarylplatinum(II) compounds containing a bidentate 287 
[N,N′] ligand (2b−2d) and cyclometalated platinum compounds containing a terdentate [C,N,N′] ligand 288 
with either a five-membered platinum(IV) (4a) or a seven-membered platinum(II) (5b−5d) metallacycle. 289 
The fluoro substituent in the aryl group remains para to the platinum in coordination compounds 2 and 290 
in the cyclometalated platinum(IV) compound 4a. However, for compounds 5 the fluoro group is now 291 
para to the formed Caryl−Caryl bond and meta to the platinum center. This result is consistent with a 292 
process involving Caryl−Caryl coupling between the carbon atoms bound to platinum of the metalated 293 
aryl ring and the para-fluoroaryl ligand, as expected for a biaryl reductive elimination from a 294 
platinum(IV) compound. On the other hand, the failure to obtain pure 3c could be related to the presence 295 
of electron-withdrawing fluorosubstituents that reduce the nucleophilic character of compound A 296 
compared to previously reported precursors.  297 
The new compounds exhibited notable to great antiproliferative activities against the A549 human lung 298 
cancer cell line. The behavior of compounds 5 is very similar to that obtained for analogous seven-299 
membered platinacycles, which suggests that the presence of fluoro substituents is not relevant to their 300 
biological properties. In spite of the very high potency of compound 2c (ca. 50-fold greater than the 301 
standard reference cisplatin), electrophoretic studies carried out for this compound do not show any 302 
evidence of either covalent binding or intercalation with DNA, nor a topoisomerase I inhibitor behavior. 303 
The results presented here constitute the first step of current work centered on (i) mechanistic studies for 304 
elucidating the mode of action of compounds 2b−2d and 4a in terms of cell cycle arrest, induction of 305 
apoptosis, etc., and (ii) structure−activity relationship analysis upon platinum(IV) complex 4a and 306 
structurally related analogues, previously synthesized in our group, in order to elucidate the structural 307 
requirements for activity. These studies may provide valuable information for the design of new 308 
organometallic compounds with improved potency and pharmacokinetic properties.  309 
  310 
EXPERIMENTAL SECTION 311 
 312 
General Procedures. Microanalyses were performed at the Centres Cientifí cs i Tecnolog̀ ics 313 
(Universitat de Barcelona). Mass spectra were performed at the Unitat d’Espectrometria de Masses 314 
(Universitat de Barcelona) in an LC/MSD-TOF spectrometer using H2O−CH3CN (1:1) to introduce the 315 
sample. NMR spectra were performed at the Unitat de RMN d’Alt Camp de la Universitat de Barcelona 316 
using a Mercury-400 (1H, 400 MHz; 1H−1H COSY; 1H−1H NOESY; 1H−13C HSQC; 13C, 100.6 317 
MHz; 19F, 376.5 MHz) or a Varian VNMRS-400 (195Pt, 85.68 MHz) spectrometer and referenced to 318 
SiMe4 (1H, 13C), CFCl3 (19F), or H2PtCl6 in D2O (195Pt). δ values are given in ppm, and J values in 319 
Hz. Abbreviations used: s = singlet; d = doublet; t = triplet; m = multiplet; br = broad.  320 
X-ray Diffraction. Suitable crystals were grown in dichloromethane−methanol at room temperature. 321 
For 2d, X-ray diffraction data were collected on a Mar 345 diffractometer with image plate detector at 322 
293 K, and the structure was solved by direct methods using the SHELX97 software package and 323 
refined by the full-matrix least-squares method with the SHELX97 software package.31 For A, 4a, and 324 
5d X-ray diffraction data were collected on a D8 VENTURE system equipped with a multilayer 325 
monochromator and a Mo high brilliance Incoatec Microfocus Source (λ = 0.71073 Å) at 100 K (A and 326 
5d) or 90 K (4a), and the structures were solved and refined using the Bruker SHELXTL software 327 
package.31 For 5d, the compound displays molecular disorder for all atoms except for Pt, C1, and C17, 328 
which lie on a mirror plane. CIFs for all four structures and a table of crystallographic data are included 329 
in the Supporting Information. 330 
Preparation of the Complexes. Ligands 1a−1d19,32 and compound cis-[PtCl2(SEt2)2]33 were 331 
prepared as reported elsewhere. Compound [Pt2(4-FC6H4)4(μ-SEt2)2] (A) was prepared using the 332 
following procedure: 3.5 mL (37.15 mmol) of n-butyllithium in hexane was added under N2 to 30 mL of 333 
diethyl ether, and the solution was cooled to 0 °C. 4-Fluoroiodobenzene (1.225 g; 5.52 mmol) was 334 
slowly added, and the mixture was stirred for 30 min at 0 °C After this time, [PtCl2(SEt2)2] (0.502 g; 335 
1.23 mmol) was added, and the mixture was stirred for 2 h at room temperature. After cooling to 0 °C, 336 
water (5 mL) was added, the aqueous layer was extracted with dichloromethane (3 × 15 mL), and the 337 
combined organic layers were dried over magnesium sulfate, filtered, and evaporated to give an oily 338 
residue. The solid obtained upon addition of hexane was filtered and dried under vacuum. Yield: 314 mg 339 
(53.8%). 1H NMR (400 MHz, CDCl3): δ 7.20 (dd, 3JH−H = 8.8, 4JH−F = 6.4, 8H, Hortho), 6.72 (dd, 340 
3JH−H = 8.8, 3JH−F = 9.2, 8H, Hmeta), 2.51 (q, 3JH−H = 7.2, 8H, CH2), 1.82 (t, 3JH−H = 7.2, 12H, 341 
CH3). 19F NMR (376.5 MHz, CDCl3): δ −121.6 (tt, 4JF−H = 6.4, 3JF−H = 9.4). HRMS-ESI-(+) 342 
{H2O−CH3CN (1:1)}: m/z 968.1805 (calcd for C32H40F4NPt2S2 968.1828) [M + NH4]+. Anal. 343 
Found (calcd) for C32H36F4Pt2S2: C: 40.3 (40.4); H: 3.9 (3.8); S: 6.9 (6.7). 344 
Compound [Pt(4-FC6H4)2{Me2NCH2CH2N=CH(2,6-Cl2C6H3)}] (2b) was obtained after stirring for 4 345 
h a mixture containing 0.100 g (0.105 mmol) of cis-[Pt(4-FC6H4)2(μ-SEt2)]2 and 0.055 g (0.224 mmol) 346 
of ligand 1b in toluene at room temperature. The solvent was evaporated, and the residue was treated 347 
with diethyl ether. The yellow solid was filtered and dried under vacuum. Yield: 106 mg (80.2%). 1H 348 
NMR (400 MHz, CDCl3): δ 8.71 (s, 3JH−Pt = 54.4, 1H, CHN), 7.26 (m, 2H, Hmeta), 6.97 (br s, 3H, 349 
HAr), 6.77 (m, 2H, Hmeta), 6.62 (m, 2H, Hortho), 6.14 (m, 2H, Hortho), 4.18 (t, 3JH−H = 5.6, 2H, 350 
CH2), 2.81 (t, 3JH−H = 5.6, 2H, CH2), 2.60 (s, 3JH−Pt = 18.8, 6H, NMe2). 19F NMR (376.5 MHz, 351 
CDCl3): δ −126.7 (m, 1F), −124.9 (m, 1F). HRMS-ESI-(+) {H2O−CH3CN (1:1)}: m/z 534.0475 (calcd 352 
for C17H18Cl2FN2Pt 535.0473) [M − C6H4F]+; 652.0697 (calcd for C23H22Cl2F2N2NaPt 652,0668) 353 
[M + Na]+; 1276.1858 (calcd for C46H48Cl4F4N5Pt2 1276.1890) [2M + NH4]+. Anal. Found (calcd 354 
for C23H22Cl2F2N2Pt): C: 44.0 (43.8); H: 3.6 (3.5); N: 4.2 (4.4). 355 
Compound [Pt(4-FC6H4)2{Me2NCH2CH2NCH(4-ClC6H4)}] (2c) was obtained using the same 356 







NMR labeling for 2c: 364 
 365 
 366 
1H NMR (400 MHz, CD3COCD3): δ 9.11 (s, 3JH−Pt = 47.2, 1H, H1), 8.20 (d, 3JH−H = 8.8, 2H, H2), 367 
7.38 (dd, 3JH−H = 8.4, 4JH−F = 6.8, 2H, H7), 7.09 (d, 3JH−H = 8.4, 2H, H3), 6.84 (dd, 3JH−H = 8.8, 368 
4JH−F = 6.8, 2H, H9), 6.67 (dd, 3JH−H = 8.8, 4JH−F = 10, 2H, H8), 6.13 (dd, 3JH−H = 8.8, 3JH−F = 369 
10, 2H, H10), 4.36 (t, 3JH−H = 5.6, 2H, H4), 2.96 (t, 3JH−H = 5.6, 2H, H5), 2.67 (s, 3JH−Pt = 21.2, 370 
6H, H6). 19F NMR (376.5 MHz, CD3COCD3): δ −126.9 (tt, 3JF−H = 10.2, 4JF−H = 6.8, 1F), −126.1 371 
(tt, 3JF−H = 10.2, 4JF−H = 6.8, 1F). 195Pt NMR (85.68 MHz, CDCl3): δ −3388.6 (s). HRMS-ESI-(+) 372 
{H2O−CH3CN (1:1)}: m/z 404.0473 (calcd for C11H14ClN2Pt 404.0487) [M − 2FC6H4 − H]+; 373 
613.1484 (calcd for C23H27ClF2N3Pt 613.1503) [M + NH4]+; 1208.2616 (calcd for 374 
C46H50Cl2F4N5Pt2 1208.2669) [2M + NH4]+. Anal. Found (calcd for C23H23ClF2N2Pt·C4H10O): 375 
C: 48.5 (48.4); H: 4.6 (5.0); N: 4.3 (4.2). 376 
Compound [Pt(4-FC6H4)2{Me2NCH2CH2NCH(2-Cl-6-FC6H3)}] (2d) was obtained using the same 377 
procedure from 1d. Yield: 107 mg (82.9%). 1H NMR (400 MHz, CD3COCD3): δ 8.74 (s, 3JH−Pt = 378 
55.6, 1H, CHN, E isomer), 8.27 (s, 3JH−Pt = 26.0, 1H, CHN, Z isomer), 7.43 (m, 2H), 7.34 (t, 3JH−H = 379 
8.0, 4H), 7.08−7.02 (m, 2H), 6.87 (m, 2H), 6.78−6.71 (m, 10H), 6.14 (dd, 3JH−F = 12.0, 3JH−H = 8.0, 380 
2H), 4.20 (m, 4H, CH2), 2.81 (t, 3JH−H = 8.0, 2H, CH2), 2.78 (t, 3JH−H = 8.0, 2H, CH2), 2.62 (s, 6H, 381 
NMe2), 2.61 (s, 6H, NMe2). 19F NMR (376.5 MHz, CD3COCD3): δ −126.5 (tt, 3JH−F = 10.2, 4JH−F 382 
= 7.2, 1F), −124.8 (tt, 3JH−F = 10.2, 4JH−F = 6.8, 1F), −124.5 (tt, 3JH−F = 10.2, 4JH−F = 7.2, 1F), 383 
−124.2 (tt, 3JH−F = 10.2, 4JH−F = 6.8, 1F), −108.5 (dd, 3JH−F = 9.0, 4JH−F = 6.0, 1F), −107.5 (dd, 384 
3JH−F = 8.6, 4JH−F = 6.0 Hz, 1F). 195Pt NMR (85.68 MHz, CDCl3): δ (ppm) −3359.0 (s). HRMS-385 
ESI-(+) {H2O−CH3CN (1:1)}: m/z 518.0774 (calcd for C17H18ClF2N2Pt 518.0768) [M − FC6H4]+; 386 
614.1133 (calcd for C23H23ClF3N2Pt 614.1146) [M + H]+. Anal. Found (calcd for C23H22ClF3N2Pt): 387 
C: 45.3 (45.0); H: 4.0 (3.6); N: 4.3 (4.6).  388 
Compound [PtBr(4-FC6H4)2{Me2NCH2CH2NCHC6H4}] (4a) was obtained as a white solid 389 
following the same procedure as for compounds 2b−2d from 0.100 g (0.105 mmol) of cis-[Pt(4-390 


















1H NMR (400 MHz, CD3COCD3): δ 8.95 (s, 3JH−Pt= 47.6, 1H, H1), 7.69 (t, 3JH−Pt = 32.0, 3JH−H = 409 
4JH−F = 6.8, 2H, H8), 7.51 (d, 3JH−H = 6.8, 1H, H13), 7.21 (d, 3JH−H = 7.6, 1H, H10), 7.15 (t, 3JH−H 410 
= 6.8, 1H, H11), 7.05 (t, 3JH−H = 6.8, 1H, H12), 6.88 (dd, 3JH−Pt= 52.0, 3JH−H = 8.0, 4JH−F = 6.0, 411 
2H, H6), 6.88 (t, 3JH−F = 3JH−H = 8.7, 2H, H7), 6.62 (m, 2H, H9), 4.70 (m, 1H, H2), 4.45 (m, 2H, H3′, 412 
H2′), 3.08 (m, 1H, H3), 2.93 (s, 3JH−Pt = 11.2, 3H, H4), 2.64 (s, 3JH−Pt = 15.2, 3H, H5). 19F NMR 413 
(376.5 MHz, CD3COCD3): δ −123.2 (tt, 5JF−Pt = 12.8, 3JF−H = 9.0, 4JF−H = 6.0, 1F, F2), −122.4 (tt, 414 
5JF−Pt = 18.8, 3JF−H = 9.4, 4JF−H = 6.0, 1F, F1). 13C NMR (100 MHz, CD3COCD3): δ 171.9 (C1), 415 
161.7, 147.3, 139.0 (d, 4JH−F = 5.0, C8), 135.5 (d, 3JC−F = 6.4, C6), 134.86, 131.75, 131.6 (C10), 416 
131.5 (C11), 129.9 (C13), 128.8, 128.1, 124.1 (C12), 113.1 (d, 2JC−F = 19.6, C7), 112.9 (d, 2JC−F = 417 
19.1, C9), 66.0 (C2), 52.6 (C3), 50.0 (C4), 47.9 (C5). 195Pt NMR (85.68 MHz, CDCl3): δ −1929.6 (s). 418 
HRMS-ESI-(+) {H2O−CH3CN (1:1)}: m/z 464.1092 (calcd for C17H18FN2Pt 464.1096) [M − FC6H4 419 
− H − Br]+; 544.0354 (calcd for C17H19BrFN2Pt 544.0357) [M − FC6H4]+; 560.1469 (calcd for 420 
C23H23F2N2Pt 560.1471) [M − Br]+; 657.1006 (calcd for C23H27BrF2N3Pt 657.0998) [M + NH4]+; 421 
1199.2099 (calcd for C46H46BrF4N4Pt2 1199.2132) [2M − Br]+; 1279.1362 (calcd for 422 
C46H47Br2F4N4Pt2 1279.1393) [2M + H]+. Anal. Found (calcd for C23H23BrF2N2Pt): C: 43.2 423 
(43.2); H: 3.8 (3.6); N: 4.4 (4.4). 424 
Compound [PtCl{(3-FC6H3)(2-ClC6H3)CHNCH2CH2NMe2}] (5b) was obtained after stirring 425 
under reflux for 6 h a solution containing 0.075 g (0.119 mmol) of compound 2b. The solvent was 426 
evaporated, and the residue was treated with diethyl ether. The yellow solid was filtered and dried under 427 
vacuum. Yield: 29 mg (45.9%). 428 





1H NMR (400 MHz, CDCl3): δ 9.24 (s, 3JH−Pt = 144.0, 1H, H4), 7.51 (t, 3JH−H = 7.6, 1H, H2), 7.38 434 
(m, 1H, H8), 7.31 (d, 3JH−H = 7.6, 2H, H1,3), 6.92 (m, 1H, H9), 6.70 (m, 1H, H10), 4.52 (m, 1H, H5), 435 
3.98 (d, 2JH−H = 10.8, 1H, H5′), 3.01 (s, 3H, H7), 2.73 (m, 4H, H7′,6′), 2,61 (m, 1H, H6). 19F NMR 436 
(376.5 MHz, CDCl3): δ (ppm) −116.6 (ddd, 3JF−H = 10.5, 3JF−H = 7.9, 4JF−H = 6.0). 195Pt NMR 437 
(85.68 MHz, CDCl3): δ −3075.1 (s). HRMS-ESI-(+) {H2O−CH3CN (1:1)}: m/z 534.0466 (calcd for 438 
C17H18Cl2FN2Pt 534.0473) [M + H]+; 551.0734 (calcd for C17H21Cl2FN3Pt 551.0738) [M + 439 
NH4]+; 1084.1108 (calcd for C34H38Cl4F2N5Pt2 1084.1139) [2M + NH4]+. Anal. Found (calcd for 440 
C17H17Cl2FN2Pt): C: 37.9 (38.2); H: 3.2 (3.2); N: 4.8 (5.2).  441 
Compound [PtCl{(3-FC6H3)(2-FC6H3)CH=NCH2CH2NMe2}] (5d) was prepared using the same 442 
procedure from 2d. Alternatively, 5d was prepared as a yellow solid from 0.150 g (0.158 mmol) of 443 
compound cis-[Pt(4-FC6H4)2(μ-SEt2)]2 and 0.074 g (0.324 mmol) of ligand 1d in toluene with 444 
continuous stirring at room temperature for 4 h followed by heating under reflux for 6 h. The reaction 445 
mixture was evaporated, and the yellow oily residue was treated with dichloromethane− methanol. After 446 
cooling the mixture, a solid was produced, filtered, and dried under vacuum. Yield: 124 mg (75.9%). 447 




H NMR (400 MHz, CD3COCD3): δ 9.38 (s, 3JH−Pt = 144.4, 1H, H1), 7.69 (td, 3JH−H = 8.0, 4JH−F = 452 
6.0, 1H, H10), 7,27 (dd, 3JH−F = 10.8, 4JH−H = 2.8, 1H, H6), 7.21 (d, 3JH−H = 8.0, 1H, H9), 7.20 453 
(ddd, 3JH−F = 12.0, 3JH−H = 8.0, 4JH−H = 0.8, 1H, H11), 6.94 (dd, 3JH−H = 8.4, 4JH−F = 6.0, 1H, 454 
H8), 6.65 (td, 3JH−H = 3JH−F = 8.4, 4JH−H = 2.8, 1H, H7), 4.56 (dtd, 2JH−H = 12.8, 3JH−H= 3JH−H 455 
= 4.4, 4JH−H = 1.2, 1H, H2), 4.31 (ddd, 2JH−H = 11.6, 3JH−H = 3.6, 3JH−H = 0.4, 1H, H2′), 2.99 (s, 456 
3H, H5), 2.85 (m, 2H, H3, H3′), 2.65 (s, 3H, H4). 19F NMR (376.5 MHz, CD3COCD3): δ −120.0 (ddd, 457 
3JF−H = 11.3, 3JF−H = 8.7, 4JF−H = 6.4, 1F, F2), −118,3 (ddd, 3JF−H = 10.2, 4JF−H = 6.0, 5JF−H = 458 
2.3, 1F, F1). 13C NMR (100 MHz, CD3COCD3): δ 159.8 (C1), 133.1 (d, 3JC−F = 10.4, C10), 130.1 (d, 459 
3JC−F = 8.2, C8), 128.8 (d, 4JC−F = 2.8, C9), 125.8 (d, 2JC−F = 17.5, C6), 112.9 (d, 2JC−F = 22.2, 460 
C11), 109.4 (d, 2JC−F = 23.0, C7), 67.4 (C2), 64.8 (C3), 50.1 (C4), 47.2 (C5). 195Pt NMR (85.68 MHz, 461 
CD3COCD3): δ −3259.0 (s). HRMS-ESI-(+) {H2O− CH3CN (1:1)}: m/z 518.0759 (calcd for 462 
C17H18ClF2N2Pt 518.0768) [M + H]+; 535.1006 (calcd for C17H21ClF2N3Pt 535.1034) [M + 463 
NH4]+; 1052.1709 (calcd for C34H38Cl2F4N5Pt2 1052.1730) [2M + NH4]+. Anal. Found (calcd for 464 
C17H17ClF2N2Pt): C: 39.7 (39.4); H: 3.4 (3.3); N: 5.3 (5.4). 465 
Compound [Pt{(4-FC6H4){Me2NCH2CH2NCH(3-ClC6H3)}] (3c) was obtained as an impure solid 466 
from 0.150 g (0.158 mmol) of compound cis-[Pt(4-FC6H4)2(μ-SEt2)]2 and 0.066 g (0.313 mmol) of 467 
ligand 1c in toluene with continuous stirring at room temperature for 4 h followed by heating under 468 
reflux for 6 h. The reaction mixture was evaporated, and the yellow oily residue was treated with 469 
dichloromethane− methanol. After cooling the mixture, a solid was produced, filtered, and dried under 470 
vacuum. Analogous results were obtained when 2c was refluxed in toluene for 6 h. 1H NMR (400 MHz, 471 
CDCl3): δ 8.38 (s, 3JH−Pt = 57.2, CHN), 3.97 (t, 3JH−H = 4.0, 2H, CH2), 3.12 (t, 3JH−H = 4.0, 2H, 472 
CH2), 2.67 (s, 3JH−Pt = 20.0, 6H, NMe2). 19F NMR (376.5 MHz, CDCl3): δ (ppm) −123.4 (tt, 3JF−H 473 
= 10.2, 4JF−H = 6.8, 1F). 474 
Biological Studies. Cell Culture. Human lung carcinoma A549 cells were grown as a monolayer culture 475 
in minimum essential medium (DMEM with L-glutamine, without glucose and without sodium 476 
pyruvate) in the presence of 10% heat-inactivated fetal calf serum, 10 mM D-glucose, and 0.1% 477 
streptomycin/penicillin, in standard culture conditions (humidified air with 5% CO2 at 37 °C). 478 
Cell Viability Assay. For A549 cell viability assays, compounds were suspended in DMSO at 20 mM as 479 
stock solution. To obtain final assay concentrations, they were diluted in DMEM (final concentration of 480 
DMSO was the same for all final dilutions and always lower than 1%). The assay was performed by a 481 
variation of the MTT assay described by Mosmann et al.34 as specified by Matito and co-workers,35 482 
which is based on the ability of live cells to cleave the tetrazolium ring of the MTT, thus producing 483 
formazan, which absorbs at 550 nm. In brief, 2.5 × 103 A549 cells/well were cultured in 96-well plates 484 
for 24 h prior to the addition of different compounds at different concentrations, in triplicate. After 485 
further incubation for 72 h, the supernatant was aspirated, and 100 μL of filtered MTT (0.5 mg/mL) was 486 
added to each well. Following 1 h of incubation with the MTT, the supernatant was removed, and the 487 
precipitated formazan was dissolved in 100 Μl of DMSO. Relative cell viability, compared to the 488 
viability of untreated cells, was measured by absorbance at 550 nm on an ELISA plate reader (Tecan 489 
Sunrise MR20-301, TECAN, Salzburg, Austria). Concentrations that inhibited cell growth by 50% 490 
(IC50) after 72 h of treatment were subsequently calculated.  491 
DNA Migration Studies. Compounds were dissolved in high-purity DMSO at 10 mM as stock solution. 492 
Then, serial dilutions were made in Milli-Q water (1:1). Plasmid pBluescript SK+ (Stratagene) was 493 
obtained using QIAGEN plasmid midi kit as described by the manufacturer. Interaction of drugs with 494 
pBluescript SK+ plasmid DNA was analyzed by agarose gel electrophoresis following a modification of 495 
the method described by Abdullah et al.36 In brief, plasmid DNA aliquots (40 μg mL−1) were incubated 496 
in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) with different concentrations of the compounds 497 
(ranging from 0 to 200 μM) at 37 °C for 24 h. Final DMSO concentration in the reactions was always 498 
lower than 1%. For comparison, cisplatin and ethidium bromide were used as controls. Aliquots of 20 499 
μL of compound−DNA complexes containing 0.8 μg of DNA were subjected to 1% agarose gel 500 
electrophoresis in TAE buffer (40 mM Tris-acetate, 2 mM EDTA, pH 8.0). The gel was stained in the 501 
same buffer containing ethidium bromide (0.5 mg mL−1) and visualized and photographed under UV 502 
light. 503 
Topoisomerase I-based experiments were performed as described previously.29 Supercoiled pBluescript 504 
DNA, obtained as described above, was treated with topoisomerase I in the absence or presence of 505 
increasing concentrations of compound 2c. Assay mixtures contained supercoiled pBluescript DNA (0.8 506 
μg), calf thymus topoisomerase I (3 units), and complex 2c (0−100 μM) in 20 μL of Tris-HCl buffer (pH 507 
7.5) containing 175 mM KCl, 5 mM MgCl2, and 0.1 mM EDTA. Ethidium bromide (10 μM) was used 508 
as a control of intercalating agents. Reactions were incubated for 30 min at 37 °C and stopped by the 509 
addition of 2 μL of agarose gel loading buffer. Samples were then subjected to electrophoresis and DNA 510 
bands stained with ethidium bromide as described above. 511 
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Legends to figures 668 
 669 
Figure 1. Molecular structure of compound A. Hydrogen atoms have been omitted for clarity. Selected 670 
bond lengths (Å) and angles (deg) with estimated standard deviations: Pt(1)−C(7): 2.006(8); Pt(1)−C(1): 671 
2.015(7); Pt(1)−S(2): 2.3504(16); Pt(1)−S(1): 2,3581(19); Pt(2)−C(19): 2,029(6); Pt(2)−C(13): 2,039(7); 672 
Pt(2)−S(2): 2.3545(18); Pt(2)−S(1): 2.3705(16); C(7)−Pt(1)−C(1): 89.8(3); C(7)−Pt(1)−S(2): 96.11(11); 673 
C(1)−Pt(1)−S(1): 93.6(2); S(2)−Pt(1)−S(1): 80.45(6); C(19)−Pt(2)−C(13): 91.2(3); C(19)−Pt(2)−S(2): 674 
94.1(2); C(13)−Pt(2)−S(1): 94.53(18); S(2)−Pt(2)−S(1): 80.11(6). 675 
 676 
Scheme 1. Synthesis of Coordination and Cyclometalated Platinum Compounds from Precursor Aa 677 
 678 
Scheme 2. Isomerization and Reactivity of Compound 2b 679 
 680 
Figure 2. Molecular structure of compound 2d. Hydrogen atoms have been omitted for clarity. Selected 681 
bond lengths (Å) and angles (deg) with estimated standard deviations: Pt−C(7): 2.007(6); Pt−C(1): 682 
2.025(6); Pt−N(1): 2.096(4); Pt−N(2): 2,214(5); N(1)−C(15): 1.260(7); N(1)−C(14): 1.501(8); 683 
N(2)−C(13): 1.464(8); C(13)−C(14): 1.525(9); C(7)−Pt−C(1): 88.4(2); C(7)−Pt−N(1): 96.0(2); 684 
C(1)−Pt−N(2): 94.9(2); N(1)−Pt−N(2): 80.62(18). 685 
 686 
Figure 3. Molecular structure of compound 4a. Hydrogen atoms have been omitted for clarity. Selected 687 
bond lengths (Å) and angles (deg) with estimated standard deviations: Pt−C(1): 2.001(6); Pt−C(12): 688 
2.051(6); Pt−C(18): 2.060(7); Pt−Br: 2.5919(6); Pt−N(1): 2.082(5); Pt−N(2): 2,337(5); N(1)−C(7): 689 
1.272(8); N(1)−C(8): 1.455(8); N(2)−C(9): 1.506(8); C(8)−C(9): 1.515(9); C(1)−Pt−C(12): 95.6(2); 690 
C(1)−Pt−N(1): 81.1(2); C(12)−Pt−N(2): 104.9(2); N(1)−Pt−N(2): 78.6(2); C(1)−Pt−C(18):92.9(2); 691 
C(12)−Pt−C(18): 87.3(2); C(18)−Pt−N(1): 90.7(2); C(18)−Pt−N(2): 93.0(2); C(1)−Pt−Br: 84.76(17); 692 
C(12)−Pt−Br: 91.54(17); N(1)−Pt−Br: 90.29(15); N(2)−Pt−Br: 89.66(13). 693 
 694 
Figure 4. Molecular structure of compound 5d. The disordered moiety and the hydrogen atoms have 695 
been omitted for clarity. Selected bond lengths (Å) and angles (deg) with estimated standard deviations: 696 
Pt(1)−C(2): 1.986(7); Pt(1)−N(1): 1.992(7); Pt(1)−N(2): 2.183(6); Pt(1)−Cl(1): 2.293(2); C(1)−C(2): 697 
1.407(8); C(1)−C(7):1.513(8); N(1)−C(13): 1.272(11); N(1)−C(14): 1.483(11); N(2)−C(15): 1.505(13); 698 
C(7)−C(8): 1.406(11); C(8)−C(13): 1.463(11); C(14)−C(15): 1.505(14); C(2)−Pt(1)−N(1): 92.1(3); 699 
N(1)−Pt(1)−N(2): 82.9(3); C(2)−Pt(1)−Cl(1): 93.1(2); N(2)−Pt(1)−Cl(1): 92.0(2). 700 
 701 
Scheme 3. Formation of Compound 5d 702 
 703 
Figure 5. Inhibition of cell growth proliferation in the A549 human lung cancer cell line, after 72 h of 704 
exposure to coordination compounds (2b−2d) (top), cyclometalated compounds (4a, 5b, 5d) (bottom), 705 
and cisplatin. 706 
 707 
Figure 6. Interaction of pBluescript SK+ plasmid DNA (0.8 μg) with increasing concentrations of 708 
compounds 2, 4, and 5, cisplatin, and ethidium bromide. Lane 1: DNA only. Lane 2: 2.5 μM. Lane 3: 5 709 
μM. Lane 4: 10 μM. Lane 5: 25 μM. Lane 6: 50 μM. Lane 7: 100 μM. Lane 8: 200 μM. ccc = 710 
supercoiled closed circular DNA; oc = open circular DNA. 711 
 712 
Figure 7. Analysis of 2c as a putative DNA intercalator or topoisomerase I inhibitor. Conversion of 713 
supercoiled pBluescript plasmid DNA (0.8 μg) to relaxed DNA by the action of topoisomerase I (3 714 
units) in the absence or in the presence of increasing amounts of compound 2c was analyzed by agarose 715 
gel stained with ethidium bromide (EtBr). Also shown are the negative and positive intercalator 716 
controls, etoposide (Etop, 100 μM) and ethidium bromide (EtBr, 10 μM). Lanes 1, DNA only, lane 2, 0 717 
μM compound; lanes 3, 10 μM; lane 4, 25 μM, lane 5, 50 μM; lanes 6, 100 μM. Except for lane 1, all the 718 
lanes included topoisomerase I. ccc = supercoiled closed circular DNA form; oc = open circular DNA 719 
form. 720 
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Table 1. Cytotoxic activities on the A549 Lung Human Cancer Cell Line for Studied Compounds and 774 
Cisplatin 775 
 776 
 777 
 778 
